Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic fibrosis foundation workshop report

Pediatrics

Volumn 119, Issue 2, 2007, Pages

  Comeau, Anne Marie ^a   Accurso, Frank J ^b   White, Terry B ^c   Campbell III, Preston W ^c   Hoffman, Gary ^d   Parad, Richard B ^a,f,g   Wilfond, Benjamin S ^h,i   Rosenfeld, Margaret ^j   Sontag, Marci K ^k   Massie, John ^l   Farrell, Philip M ^e   O'Sullivan, Brian P ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b CHILDREN S HOSPITAL   (United States)

^c CYSTIC FIBROSIS FOUNDATION   (United States)

^d WISCONSIN STATE LABORATORY OF HYGIENE   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

ⁱ NATIONAL INSTITUTES OF HEALTH   (United States)

^j UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF COLORADO   (United States)

^l ROYAL CHILDREN'S HOSPITAL   (Australia)

more..

Author keywords

Cystic fibrosis; Genotype; Guidelines; Newborn screening; Sweat test

Indexed keywords

ALGORITHM; CONFERENCE PAPER; CYSTIC FIBROSIS; DEMOGRAPHY; DIAGNOSTIC TEST; HEALTH PROGRAM; HUMAN; NEWBORN SCREENING; PRIMARY MEDICAL CARE; PRIORITY JOURNAL;

ALGORITHMS; CYSTIC FIBROSIS; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; OUTCOME ASSESSMENT (HEALTH CARE); SWEAT;

EID: 33947141892     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-1993     Document Type: Conference Paper

References (97)

1. Lai HJ, Cheng Y, Farrell PM. The survival advantage of cystic fibrosis patients diagnosed through neonatal screening: evidence from the US Cystic Fibrosis Foundation Registry data. J Pediatr. 2005;147(3 suppl):S57-S63
2. McKay KO, Waters DL, Gaskin KJ. The influence of newborn screening for cystic fibrosis on pulmonary outcomes in New South Wales. J Pediatr. 2005;147(3 suppl):S47-S50
3. Sims EJ, McCormick J, Mehta G, Mehta A. Neonatal screening for cystic fibrosis is beneficial even in the context of modern treatment. J Pediatr. 2005;147(3 suppl):S42-S46
4. Farrell PM, Lai HJ, Li Z, et al. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough! J Pediatr. 2005;147(3 suppl):S30-S36
5. Dankert-Roelse JE, Mérelle ME. Review of outcomes of neonatal screening for cystic fibrosis versus non-screening in Europe. J Pediatr. 2005;147(3 suppl):S15-S20
6. Rosenfeld M. Overview of published evidence on outcomes with early diagnosis from large US observational studies. J Pediatr. 2005;147(3 suppl):S11-S14
7. Koscik RL, Farrell PM, Kosorok MR, et al. Cognitive function of children with cystic fibrosis: deleterious effect of early malnutrition. Pediatrics. 2004;113:1549-1558
8. Assael BM, Castellani C, Ocampo MB, Iansa P, Callegaro A, Valsecchi MG. Epidemiology and survival analysis of cystic fibrosis in an area of intense neonatal screening over 30 years. Am J Epidemiol. 2002;156:397-401
9. Mastella G, Zanolla L, Castellani C, et al. Neonatal screening for cystic fibrosis: long-term clinical balance. Pancreatology. 2001;1:531-537
10. Beker LT, Russek-Cohen E, Fink RJ. Stature as a prognostic factor in cystic fibrosis survival. J Am Diet Assoc. 2001;101:438-442
11. Wang SS, O'Leary LA, Fitzsimmons SC, Khoury MJ. The impact of early cystic fibrosis diagnosis on pulmonary function in children. J Pediatr. 2002;141:804-810
12. Waters DL, Wilcken B, Irwing L, et al. Clinical outcomes of newborn screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed. 1999;80:F1-F7
13. Merelle ME, Schouten JP, Gerritsen J, Dankert-Roelse JE. Influence of neonatal screening and centralized treatment on long-term clinical outcome and survival of CF patients. Eur Respir J. 2001;18:306-315
14. Farrell PM, Kosorok MR, Rock MJ, et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics. 2001;107:1-13
15. Chatfield S, Owen G, Riley HC, et al. Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after five years of screening. Arch Dis Child. 1991;66:29-33
16. Grosse SD, Boyle CA, Botkin JR, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep. 2004;53(RR-13):1-36
17. Accurso FJ, Sontag MK, Wagener JS. Complications associated with symptomatic diagnosis in infants with cystic fibrosis. J Pediatr. 2005;147(3 suppl):S37-S41
18. Wilcken B, Chalmers G. Reduced morbidity in patients with cystic fibrosis detected by neonatal screening. Lancet. 1985;2(8468):1319-1321
19. Siret D, Bretaudeau G, Branger B, et al. Comparing the clinical evolution of cystic fibrosis screened neonatally to that of cystic fibrosis diagnosed through clinical symptoms: a 10-year retrospective study in a French region (Britanny). Pediatr Pulmonol. 2003;35:342-349
20. Koscik RL, Lai HJ, Laxova A, et al. Preventing early, prolonged vitamin E deficiency: an opportunity for better cognitive outcomes via early diagnosis through neonatal screening. J Pediatr. 2005;147(3 suppl):S51-S56
21. Lai HJ, Cheng Y, Cho H, Kosorok MR, Farrell PM. Association between initial disease presentation, lung disease outcomes, and survival in patients with cystic fibrosis. Am J Epidemiol. 2004;159:537-546
22. Doull IJ, Ryley HC, Weller P, Goodchild MC. Cystic fibrosis-related deaths in infancy and the effect of newborn screening. Pediatr Pulmonol. 2001;31:363-366
23. Farrell PM, Li Z, Kosorok MR, et al. Bronchopulmonary disease in children with cystic fibrosis after early or delayed diagnosis. Am J Respir Crit Care Med. 2003;168:1100-1108
24. Lee DS, Rosenberg MA, Peterson A, et al. Analysis of the costs of diagnosing cystic fibrosis with a newborn screening program. J Pediatr. 2003;142:617-623
25. Massie J, Freezer N, Wilson J, Robertson C. Clinical diagnosis of cystic fibrosis in a screened community: 1989-1998 [abstract]. Pediatr Pulmonol. 2000;(suppl 20):297-298
26. Dankert-Roelse JE, Tijmstra T, Knol K, ten Kate LP. Screening for cystic fibrosis; interviews with parents of children with a false-positive test result [in Dutch]. Ned Tijdschr Geneeskd. 1983;127:2136-2139
27. Tluczek A, Mischler EH, Farrell PM, Fost N, Peterson NM, Carey P. Parents' knowledge of neonatal screening and response to false-positive cystic fibrosis testing. J Dev Behav Pediatr. 1992;13:181-186
28. Mischler EH, Wilfond BS, Fost N, et al. Cystic fibrosis newborn screening: impact on reproductive behavior and implications for genetic counseling. Pediatrics. 1998;102:44-52
29. Ciske DJ, Haavisto A, Laxova A, Rock LZ, Farrell PM. Genetic counseling and neonatal screening for cystic fibrosis: an assessment of the communication process. Pediatrics. 2001;107:699-705
30. Wheeler P, Smith R, Dorkin H, Parad R, Comeau A, Bianchi D. Genetic counseling after implementation of statewide cystic fibrosis newborn screening: two years' experience in one medical center. Genet Med. 2001;3:411-415
31. Parad R, Estrella E, Comeau A, Hawley P. Attitude toward CF newborn screening after receiving false positive results: impact of genetic counseling on parents identified as carriers [abstract]. Pediatr Pulmunol. 2004;(suppl 27):226
32. MacCready R. Phenylketonuria screening programs. N Engl J Med. 1963;269:52-53
33. Serving the family from birth to the medical home: a report from the Newborn Screening Task Force convened in Washington DC, May 10-11, 1999. Pediatrics. 2000;106:383-427
34. New England Regional Genetics Group. Position Statement: State Newborn Screening Advisory Committees. Newton, ME: New England Regional Genetics Group; 2000:1-2
35. Whitehead F, Couper R, Moore L, Bourne A, Byard R. Dehydration deaths in infants and young children. Am J Forensic Med Pathol. 1996;17:73-78
36. Comeau AM, Parad RB, Dorkin HL, et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics. 2004;113:1573-1581
37. Rock MJ, Hoffman G, Laessig RH, Kopish GJ, Litsheim TJ, Farrell PM. Newborn screening for cystic fibrosis in Wisconsin: nine years experience with routine trypsinogen/DNA testing. J Pediatr. 2005;147(3 suppl):S73-S77
38. Sontag MK, Hammond KB, Zielenski J, Wagener JS, Accurso FJ. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. J Pediatr. 2005;147(3 suppl):S83-S88
39. Crossley JR, Elliott RB, Smith PA. Dried-blood spot screening for cystic fibrosis in the newborn. Lancet. 1979;1(8114):472-474
40. Wilfond BS, Gollust SE. Policy issues for expanding newborn screening programs: the cystic fibrosis newborn screening experience in the United States. J Pediatr. 2005;146:668-674
41. Wagener JS, Sontag MK, Accurso F. Newborn screening for cystic fibrosis. Curr Opin Pediatr. 2003;15:309-315
42. Rusakow LS, Abman SH, Sokol RJ, Seltzer W, Hammond K, Accurso FJ. Immunoreactive trypsinogen levels in infants with cystic fibrosis complicated by meconium ileus. Screening. 1993;2:13-17
43. Rock MJ, Mischler EH, Farrell PM, Bruns WT, Hassemer DJ, Laessig RH. Immunoreactive trypsinogen screening for cystic fibrosis: characterization of infants with a false-positive screening test. Pediatr Pulmonol. 1989;6:42-48
44. Hassemer DJ, Laessig RH, Hoffman GL, Farrell PM. Laboratory quality control issues related to screening newborns for cystic fibrosis using immunoreactive trypsin. Pediatr Pulmonol Suppl. 1991;7:76-83
45. Gregg RG, Simantel A, Farrell PM, et al. Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods. Pediatrics. 1997;99:819-824
46. - channels with altered pore properties. Nature. 1993;362:160-164
47. Braun AT, Farrell PM, Ferec C, et al. Cystic fibrosis mutations and genotype-pulmonary phenotype analysis. J Cyst Fibros. 2006;5:33-41
48. Massie J, Curnow L, Tzanakos N, Francis I, Robertson C. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing. Arch Dis Child. 2005;91:222-225
49. Comeau AM, Parad R, Gerstle R, et al. Challenges in implementing a successful newborn CF screening program. J Pediatr. 2005;147(3 suppl):S89-S93
50. LeGrys VA, Burritt MF, Gibson LE, Hammond KB, Kraft K, Rosenstein BJ. Sweat Testing: Sample Collection and Quantitative Analysis. Approved Guideline. Villanova, PA; National Committee for Clinical Laboratory Standards; 1994. National Committee for Clinical Laboratory Standards document C34-A
51. Saiman L, Siegel J; Cystic Fibrosis Foundation. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol. 2003;24(5 suppl):S6-S52
52. Mackay R, George P, Kirk J. Sweat testing for cystic fibrosis: a review of New Zealand laboratories. J Paediatr Child Health. 2006;42:160-164
53. Massie J. Sweat testing for cystic fibrosis: how good is your laboratory? J Paediatr Child Health. 2006;42:153-154
54. Hardy JD, Davison SH, Higgins MU, Polycarpou PN. Sweat tests in the newborn period. Arch Dis Child. 1973;48:316-318
55. Farrell PM, Koscik RE. Sweat chloride concentrations in infants homozygous or heterozygous for F508 cystic fibrosis. Pediatrics. 1996;97:524-528
56. Eng W, LeGrys V, Schechter M, Laughon M, Barker P. Sweat testing in pre-term and full-term infants less than 6 weeks of age. Pediatr Pulmonol. 2005;40:64-67
57. Rosenstein B, Cutting G. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr. 1998;132:589-595
58. Rosenstein BJ, Langbaum TS. Misdiagnosis of cystic fibrosis: need for continuing follow-up and reevaluation. Clin Pediatr (Phila). 1987;26:78-82
59. Rosenstein BJ, Langbaum TS, Gordes E, Brusilow SW. Cystic fibrosis: problems encountered with sweat testing. JAMA. 1978;240:1987-1988
60. Parad RB, Comeau AM, Dorkin HL, et al. Sweat testing newborn infants detected by cystic fibrosis newborn screening. J Pediatr. 2005;147(3 suppl):S69-S72
61. Padoan R, Bassotti A, Seia M, Corbetta C. Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations. Eur J Pediatr. 2002;161:212-215
62. Desmarquest P, Feldmann D, Tamalat A, et al. Genotype analysis and phenotypic manifestations of children with intermediate sweat chloride test results. Chest. 2000;118:1591-1597
63. Parsons EP, Clarke AJ, Bradley DM. Implications of carrier identification in newborn screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed. 2003;88:F467-F471
64. Dillard J, Carson C, Bernard C, Laxova A, Farrell PM. An analysis of communication following newborn screening for cystic fibrosis. Health Commun. 2004;16:197-205
65. Ahmed N, Corey M, Forstner G, et al. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut. 2003;52:1159-1164
66. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet. 2003;361:1671-1676
67. Parad RB, Comeau AM. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm. J Pediatr. 2005;147(3 suppl):S78-S82
68. Wilfond BS, Parad RB, Fost N. Balancing benefits and risks for cystic fibrosis newborn screening: implications for policy decisions. J Pediatr. 2005;147(3 suppl):S109-S113
69. Parsons E, Bradley D. Psychosocial issues in newborn screening for cystic fibrosis. Paediatr Respir Rev. 2003;4:285-292
70. Super M. Cystic fibrosis newborn screening and detection of carriers. Arch Dis Child Fetal Neonatal Ed. 2003;88:F448-F449
71. National Society of Genetic Counselors. Genetic counseling as a profession. 2005. Available at: www.nsgc.org/about/definition.cfm. Accessed June 27, 2006
72. Langfelder-Schwind E, Rosenblatt MJ, Caine E, et al. Genetic counseling follow up for parents of CF gene mutation carriers identified through newborn screening in New York State. Pediatr Pulmonol. 2003;(suppl 25):224
73. Comeau AM, Parad R, Gerstle R, et al. Communications systems and their models: Massachusetts parent compliance with recommended specialty care following positive CF newborn screen. J Pediatr. 2005;147(3 suppl):S98-S100
74. Weil J. Psychosocial genetic counseling in the post-nondirective era: a point of view. J Genet Couns. 2003;12:199-211
75. Grody WW, Cutting GR, Klinger KW, et al. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med. 2001;3:149-154
76. Curnow L, Savarirayan R, Massie J. Genetic counseling after carrier detection by newborn screening when one parent carries DeltaF508 and the other R117H. Arch Dis Child. 2003;88:886-888
77. Rohlfs EM, Zhou Z, Sugarman EA, et al. The I148T CFTR allele occurs on multiple haplotypes: a complex allele is associated with cystic fibrosis. Genet Med. 2002;4:319-323
78. Saiman L, Siegel J. Infection control in cystic fibrosis. Clin Microbiol Rev. 2004;17:57-71
79. Watson MS, Doyle DL, Johnson KA. Financing genetics and newborn screening services archive [Webcast]. 2005. Available at: www.mchcom.com/ archivedWebcastDetailNewInterface.asp?aeid-337. Accessed June 27, 2006
80. Wilcken B, Wiley V, Sherry G, Bayliss U. Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1.2 million babies. J Pediatr. 1995;127:965-970
81. Parad R, Comeau AM, Eaton R, et al. Impact of CF newborn screening on pediatrician's decision to sweat test screened infants with CF-like symptoms. Paper presented at: 14th National Neonatal Screening Symposium; St Louis, MO; September 7-10, 1999
82. California Department of Health Services, Center for Health Statistics Vital Query System. Birth records 2003. Available at: www.applications.dhs.ca. gov/vsq/default.asp. Accessed June 27, 2006
83. US Census Bureau, Population Division. Population estimates by state: annual estimates of the population by sex, race, and Hispanic or Latino origin for states: April 1, 2000 to July 1, 2004. 2005. Available at: www.census.gov/popest/states/asrh/SC-EST2004-03.html. Accessed June 27, 2006
84. Heim R, Sugarman E, Allitto B. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded, pan-ethnic mutation panel. Genet Med. 2001;3:168-176
85. Macek MJ, Mackova A, Hamosh A, et al. Identification of common cystic fibrosis mutations in African-Americans with cystic fibrosis increases the detection rate to 75%. Am J Hum Genet. 1997;60:1122-1127
86. Alper OM, Wong LJ, Young S, et al. Identification of novel and rare mutations in California Hispanic and African American cystic fibrosis patients [published correction appears in Hum Mutat. 2005;25:223]. Hum Mutat. 2004;24:353
87. Massie J, Clements B. Diagnosis of cystic fibrosis after newborn screening: the Australasian experience - twenty years and five million babies later: a consensus statement from the Australasian Pediatric Respiratory Group. Pediatr Pulmonol. 2005;39:440-446
88. Massie RJ, Poplawski N, Wilcken B, Goldblatt J, Byrnes C, Robertson C. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. Eur Respir J. 2001;17:1195-1200
89. Augarten A, Kerem BS, Yahav Y, et al. Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C>T mutation. Lancet. 1993;342:25-26
90. Gan KH, Veeze HJ, van den Ouweland AM, et al. A cystic fibrosis mutation associated with mild lung disease. N Engl J Med. 1995;333:95-99
91. Highsmith WE, Burch LH, Zhou Z, et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med. 1994;331:974-980
92. Kiesewetter S, Macek M Jr, Davis C, et al. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet. 1993;5:274-278
93. -] < 30 meq/L [abstract]. Pediatr Pulmonol. 2005;(suppl 28):256
94. Groman JD, Hefferon TW, Casals T, et al. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet. 2004;74:176-179
95. Cuppens H, Lin W, Jaspers M, et al. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes: the polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest. 1998;101:487-496
96. Massie RJ, Wilcken B, Van Asperen P, et al. Pancreatic function and extended mutation analysis in DeltaF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels. J Pediatr. 2000;137:214-220
97. Parad RB, Comeau AM. Newborn screening for cystic fibrosis. Pediatr Ann. 2003;32:528-535